Direkt zum Inhalt
Startseite

Dedicated to discovery

  • Über ELGA
    • Über ELGA
    • Karriere
    • Veranstaltungen
  • Service
    • Laborplanung
  • Kontakt
  • EN
  • ES
  • FR
  • IT
  • PT
  • EN-US
Startseite
  • Produkte
    • PURELAB
      • PURELAB® Dispenser
      • PURELAB® Flex
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • PURELAB® Chorus 2 +
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 150
      • MEDICA® 7/15
      • MEDICA® BIOX 2024
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY 30
    • Komplette Produktpalette
  • Anwendungen
    • Allgemeiner Laborwasserbedarf
    • Atomspektroskopie
    • Elektrochemie
    • Flüssigchromatographie
      • High Performance Liquid Chromatography
    • Gaschromatographie
    • Genetik
    • High Performance Liquid Chromatography (HPLC)
    • Immunchemie
    • Klinische Biochemie
    • Massenspektrometrie
    • Mikrobiologische Analyse
    • Spektrophotometrie
    • Zellkulturen
  • Technologien
    • Aktivkohle
    • Elektroentionisierung (EDI)
    • Filtration
    • Ionenaustausch
    • PureSure
    • Ultraviolettes Licht (UV)
    • Umkehrosmose (RO)
  • Verunreinigungen im Wasser
    • Anorganische Verbindungen
    • Gelöste Gase
    • Mikroorganismen und Bakterien
    • Organische Verbindungen
    • Partikel
  • Wissen
    • BROSCHÜREN
    • Blog
    • Referenzen
    • Reinstwasser
    • Whitepaper rund um Laborwasser
  • Where to buy
  • Kontakt
Home
  • Kontakt
  • Produkte
    • PURELAB
      • PURELAB® Dispenser
      • PURELAB® Flex
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • PURELAB® Chorus 2 +
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 150
      • MEDICA® 7/15
      • MEDICA® BIOX 2024
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY 30
    • Komplette Produktpalette
  • Anwendungen
    • Allgemeiner Laborwasserbedarf
    • Atomspektroskopie
    • Elektrochemie
    • Flüssigchromatographie
      • High Performance Liquid Chromatography
    • Gaschromatographie
    • Genetik
    • High Performance Liquid Chromatography (HPLC)
    • Immunchemie
    • Klinische Biochemie
    • Massenspektrometrie
    • Mikrobiologische Analyse
    • Spektrophotometrie
    • Zellkulturen
  • Technologien
    • Aktivkohle
    • Elektroentionisierung (EDI)
    • Filtration
    • Ionenaustausch
    • PureSure
    • Ultraviolettes Licht (UV)
    • Umkehrosmose (RO)
  • Verunreinigungen im Wasser
    • Anorganische Verbindungen
    • Gelöste Gase
    • Mikroorganismen und Bakterien
    • Organische Verbindungen
    • Partikel
  • Wissen
    • BROSCHÜREN
    • Blog
    • Referenzen
    • Reinstwasser
    • Whitepaper rund um Laborwasser
  • Where to buy
  • Kontakt
  • Über ELGA
    • Über ELGA
    • Karriere
    • Veranstaltungen
  • Service
    • Laborplanung
  • Kontakt
  • EN
  • ES
  • FR
  • IT
  • PT
  • EN-US
  • Datenschutzerklärung
  • Geschäftsbedingungen
  • Globale Entsprechenserklärungen
  • Patente
  • Trademarks
  • Impressum
  • Improving Treatment for Patients with Kidney Disease
Clinical & Pharma
Science of the Future

Improving Treatment for Patients with Kidney Disease

11 März 2020
- by Dr Alison Halliday

Happy senior lady sitting at wheelchair in nursing home for elderly

Difficulties for Patients Achieving Target Blood Phosphate Levels

Patients on dialysis are at risk of developing hyperphosphatemia, a serious and potentially life-threatening condition. A new study looks at factors that may influence the clinical effectiveness of drugs which aim to lower blood phosphate levels.

People with late-stage chronic kidney disease (CKD) have problems with removing phosphate from their bodies, leading to increased levels in their blood. This condition, known as hyperphosphatemia, can make patients receiving dialysis feel very ill and put them at an increased risk of death.

Treatment with drugs that bind phosphate in the gastrointestinal (GI) tract aim to reduce its absorption into their bloodstream. But many patients still don’t reach the target levels for blood phosphate, despite taking phosphate binders and restricting their diet.

The reasons why phosphate-binding treatments don’t always have the desired effects are complex, but they may include patients not taking the drugs correctly, not following their diet, or the phosphate coming from elsewhere in the body, such as from their bones. However, factors that influence the ability of phosphate binders to bind phosphate may also have an impact. 

Acid Testing with Ultrapure Water

A team of researchers carried out a series of laboratory tests to explore the influence of pH and phosphate concentration on the phosphate-binding capabilities of five existing drugs used to treat patients with hyperphosphatemia.1 
 
To do this, they measured the phosphate-binding capacity of each drug in solutions with different pH values and phosphate concentrations. An ELGA PURELAB flex water purification system provided the ultrapure water for making all phosphate solutions and pH media.

All five drugs bound more phosphate within solutions containing higher concentrations of phosphate and, with the exception of one drug, they also performed better in the more acidic solutions. However, the differences were all small except for lanthanum carbonate, which doubled it binding capacity at pH 3.0. 

Clinical Impact & Improving Treatment

Although more work will be needed to find out if these laboratory results extrapolate to the complex GI environment where additional factors such as the presence of bile salts, passage time through the stomach and intestines, or the use of food additives, may introduce more variability into a drug’s phosphate binding capacity.

But should they hold true within the body, the influence of pH may be particularly relevant as the levels of stomach acidity in a patient could impact on drug effectiveness. Doctors would, therefore, need to consider other factors that may affect this, such as if a patient is also taking proton pump inhibitors, has just eaten a meal, or are experiencing chronic gastritis.
 
The results from this study shed new light on the pharmacology of phosphate-binding drugs and could help improve the treatment for patients with end-stage kidney disease in the future.

How Can ELGA Help You?

ELGA’s expert engineers, chemists and scientists are at the forefront of technological innovation. We continue to introduce game-changing features to the lab water market.
 


Reference:
Schumacher, S. P., et al., Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study. Nephrology 2018, Feb 26. doi: 10.1111/nep.13245

 

Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

  • Sales Enquiry
  • Angebot anfordern
  • Technical Support
  • Einen Ansprechpartner finden

Sales Enquiry

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

Ich habe die Datenschutzerklärung gelesen und verstanden

Angebot anfordern

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

Ich habe die Datenschutzerklärung gelesen und verstanden

Technical Support

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater Deutschland

ELGA LabWater
Veolia Water Technologies Deutschland GmbH
Speicherstraße 14 A
29221 Celle
T: +49 (0) 51 41 803 0
F: +49 (0) 51 41 803 384

Referenzen

  • Abbott Diagnostics
  • DASA Medical Diagnostics
  • NeoDIN Medical Institute
  • North Staffordshire NHS Trust
  • Berufskolleg Olsberg

Ressourcen

  • Erfahren Sie mehr über Reinstwasser
  • Whitepaper rund um Laborwasser
  • Technologien zur Wasseraufbereitung
  • Laboranwendungen
  • Verunreinigungen im Wasser
  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?

© VWS (UK) Ltd, handelnd als ELGA LabWater.2025- Alle Rechte vorbehalten.
ELGA ist der globale Markenname von Veolia für Laborwasser.

  • Datenschutzerklärung
  • Geschäftsbedingungen
  • Globale Entsprechenserklärungen
  • Patente
  • Trademarks
  • Impressum
  • Sprache
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Andere Veolia Webseiten
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies
Elga Veolia
TOP

© 2017 ELGA Veolia